Drug news

HaemoCloud announced by Haemonetics, a sotware device to connect Haemonetics blood management devices to communicate with hospital information systems.

Read time: 1 mins

Last updated:12th Aug 2015

Published:12th Aug 2015

Source: Pharmawand

Haemonetics announced HaemoCloud, an award-winning Internet of Things ("IoT") software platform designed to connect all Haemonetics devices and software, creating unprecedented control of the blood management supply chain. HaemoCloud is a foundational suite of products including HaemoCommunicator and HaemoCloud, which allow Haemonetics blood management devices to communicate with hospital information systems and provide real-time device operational data for service and support.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

The FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia below-the-knee

Abbott announced that the FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK)

2 mins

Drug news

Promising findings in phase IIb/III clinical trial of NRX 101 vs. lurasidone for treatment of suicidal bipolar depression

NRx Pharmaceuticals, Inc. announced that its Breakthrough Therapy designated investigational drug NRX 101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduction in symptoms of akathisia – a side effect of antidepressants that is closely linked to suicide and considered a medical emergency

1 min

Drug news

FDA approval of Ingrezza Sprinkle (valbenazine) capsules for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease

Neurocrine Biosciences, Inc. announced the FDA has approved Ingrezza Sprinkle (valbenazine) capsules, a new oral granules formulation of Ingrezza (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease

1 min

See all news